ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- miRNA-mediated resistance mechanisms in prostate cancer: implications for targeted therapy and metastatic progression.Medical oncology (Northwood, London, England) · 2025Review
- Integrated analysis of the potential roles of microRNA-messenger RNA networks in prostate adenocarcinoma.Heliyon · 2023Article
- Review
- Loss of miR-936 leads to acquisition of androgen-independent metastatic phenotype in prostate cancer.Scientific reports · 2022Article
- Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment.Pharmaceutics · 2022Review
- MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors inInternational journal of molecular sciences · 2021Article
- Clinical value of microRNA-135a and MMP-13 in colon cancer.Oncology letters · 2021Article
- miR‑135a‑5p inhibits tumor invasion by targeting ANGPT2 in gallbladder cancer.Molecular medicine reports · 2021Article
- Abnormal expression of miR-135a in patients with depression and its possible involvement in the pathogenesis of the condition.Experimental and therapeutic medicine · 2021Article
- miR-135a Reduces Osteosarcoma Pulmonary Metastasis by Targeting Both BMI1 and KLF4.Frontiers in oncology · 2021Article
- Cell-free nucleic acid patterns in disease prediction and monitoring-hype or hope?The EPMA journal · 2020Review
- MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy.Cancer biology & medicine · 2020Review
- MicroRNA-135a Protects Against Ethanol-Induced Apoptosis in Neural Crest Cells and Craniofacial Defects in Zebrafish by Modulating the Siah1/p38/p53 Pathway.Frontiers in cell and developmental biology · 2020Article
- Sulforaphane Induces miR135b-5p and Its Target Gene, RASAL2, thereby Inhibiting the Progression of Pancreatic Cancer.Molecular therapy oncolytics · 2019Article
- Potential Five-MicroRNA Signature Model for the Prediction of Prognosis in Patients with Wilms Tumor.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- miR-135 regulated breast cancer proliferation and epithelial-mesenchymal transition acts by the Wnt/β-catenin signaling pathway.International journal of molecular medicine · 2019Article
- MicroRNA-155 inhibits the osteogenic differentiation of mesenchymal stem cells induced by BMP9 via downregulation of BMP signaling pathway.International journal of molecular medicine · 2018Article
- Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model.Journal of translational medicine · 2018Article
- miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer.Scientific reports · 2018Article
- MicroRNA-135a regulates NHE9 to inhibit proliferation and migration of glioblastoma cells.Cell communication and signaling : CCS · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is one of the leading causes of death in men worldwide. Differentially expressed microRNAs (miRNAs) are associated with metastatic prostate cancer. However, their potential roles for affecting prostate cancer initiation and progression remain largely unknown. Here, we examined the aberrant expression profiles of miRNAs in human metastatic prostate cancer tissues. We further validated our miRNA expression data using two large, independent clinical prostate cancer datasets from the Memorial Sloan Kettering Cancer Center (MSKCC) and The Cancer Genome Atlas (TCGA). Our data support a model in which hsa-miR-135-1 acts as a potential tumor suppressor in metastatic prostate cancer. First, its downregulation was positively correlated with late TNM stage, high Gleason score, and adverse prognosis. Second, cell growth, cell cycle progression, cell migration and invasion, and xenograft tumor formation were dramatically inhibited by miR-135a overexpression. Third, in the microarray gene expression data analysis using Gene Set Enrichment Analysis (GSEA), Database for Annotation, Visualization and Integrated Discovery (DAVID) analysis, Ingenuity Pathway Analysis (IPA), and Oncomine concept analysis, we showed that miR-135a targets multiple oncogenic pathways including epidermal growth factor receptor (EGFR), which we verified using functional experimental assays. These results help advance our understanding of the function of miRNAs in metastatic prostate cancer and provide a basis for further clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.